Interactions between Calmodulin, Adenosine A$_{2A}$, and Dopamine D$_2$ Receptors*

Gemma Navarro[‡], **Marisol S. Aymerich**[§], **Daniel Marcellino**[¶], **Antoni Cortés**[‡], **Vicent Casadó**[‡], **Josefa Mallol**[‡], **Enric I. Canela**[‡], **Luigi Agnati**[¶], **Amina S. Woods**[‖], **Kjell Fuxe**[¶], **Carmen Lluís**[‡], **Jose Luis Lanciego**[§], **Sergi Ferré**[‖], **and Rafael Franco**[‡§1]

From the [‡]Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas, and Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona, 08028 Barcelona, Spain, [§]Centro de Investigación Médica Aplicada Neurociencias (CIMA), Universidad de Navarra, Avda. Pio XII 55, 31008 Pamplona, Spain, the [¶]Department of Neuroscience, Karolinska Institute, 17177 Stockholm, Sweden, and the [‖]National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, Maryland 21224

The Ca^{2+}-binding protein calmodulin (CaM) has been shown to bind directly to cytoplasmic domains of some G protein-coupled receptors, including the dopamine D$_2$ receptor. CaM binds to the N-terminal portion of the long third intracellular loop of the D$_2$ receptor, within an Arg-rich epitope that is also involved in the binding to G$_{i/o}$ proteins and to the adenosine A$_{2A}$ receptor, with the formation of A$_{2A}$-D$_2$ receptor heteromers. In the present work, by using proteomics and bioluminescence resonance energy transfer (BRET) techniques, we provide evidence for the binding of CaM to the A$_{2A}$ receptor. By using BRET and sequential resonance energy transfer techniques, evidence was obtained for CaM-A$_{2A}$-D$_2$ receptor oligomerization. BRET competition experiments indicated that, in the A$_{2A}$-D$_2$ receptor heteromer, CaM binds preferentially to a proximal C terminus epitope of the A$_{2A}$ receptor. Furthermore, Ca^{2+} was found to induce conformational changes in the CaM-A$_{2A}$-D$_2$ receptor oligomer and to selectively modulate A$_{2A}$ and D$_2$ receptor-mediated MAPK signaling in the A$_{2A}$-D$_2$ receptor heteromer. These results may have implications for basal ganglia disorders, since A$_{2A}$-D$_2$ receptor heteromers are being considered as a target for anti-parkinsonian agents.

G-protein-coupled receptors are able to form homo- and hetero-oligomers with unique biochemical and functional characteristics (1–7), and they are easily detected *in vitro* by using biophysical techniques (8–10). Heteromers of adenosine A$_{2A}$ and dopamine D$_2$ receptors were one of the first G-protein-coupled receptor heteromers to be described (11). A close physical interaction between both receptors was shown using co-immunoprecipitation and co-localization assays (11) and fluorescence and bioluminescence resonance energy transfer (FRET[2] or BRET) techniques (12–14). At the biochemical level, two types of antagonistic A$_{2A}$-D$_2$ receptor interactions have been discovered that may explain the A$_{2A}$-D$_2$ receptor interactions described both at the neuronal and behavioral level (11, 15–18). First, by means of an allosteric interaction in the receptor heteromer, stimulation of A$_{2A}$ receptor decreases the affinity of D$_2$ receptor for their agonists (12). Second, the stimulation of the G$_{i/o}$-protein-coupled D$_2$ receptor inhibits the cAMP accumulation induced by the stimulation of the G$_{s/olf}$-protein-coupled A$_{2A}$ receptor (11, 17, 18). In view of the well known role of dopamine in Parkinson disease, schizophrenia, and drug addiction, it has been suggested that the A$_{2A}$-D$_2$ receptor interactions in the central nervous system may provide new therapeutic approaches to combat these disorders (16, 19).

An epitope-epitope electrostatic interaction between an Arg-rich epitope of the N terminus of the third intracellular loop (3IL) of the D$_2$ receptor and an epitope containing a phosphorylated Ser localized in the distal part of the C terminus of the A$_{2A}$ receptor is involved in A$_{2A}$-D$_2$ receptor heteromer interface (14, 20, 21). The same Arg-rich epitope of the D$_2$ receptor is able to interact with CaM (22–25). In the absence of phosphorylated residues, adjacent aspartates or glutamates, which are abundant in CaM, may also form non-covalent complexes with Arg-rich epitopes (26). Therefore, CaM can potentially convey a Ca^{2+} signal to the D$_2$ receptor through direct binding to the 3IL of the D$_2$ receptor (22). Mass spectrometry data have shown that bovine CaM can form multiple non-covalent complexes with an Arg-rich peptide corresponding to the N-terminal region of the 3IL of the D$_2$ receptor (VLR-RRRKRVN) (24) as well as a peptide from the proximal C terminus of the A$_{2A}$ receptor (24). This epitope, whose sequence is ^{291}RIREFRQTFR^{300} in the human A$_{2A}$ receptor, also contains several Arg residues. Since the suspected interaction between the A$_{2A}$ receptor and CaM was awaiting confirmation by assays using complete proteins, the present study was undertaken to demonstrate the existence of interactions between the A$_{2A}$

[1] To whom correspondence should be addressed: CIMA Neurociencias, Avda. Pio XII 55, 31008 Pamplona, Spain. Tel.: 34-934021208; Fax: 34-934021559; E-mail: rfranco@unav.es.

[2] The abbreviations used are: FRET, fluorescence resonance energy transfer; BRET, bioluminescence resonance energy transfer; CaM, calmodulin; SRET, sequential resonance energy transfer; 3IL, third intracellular loop; MAPK, mitogen-activated protein kinase; GFP, green fluorescent protein; YFP, yellow fluorescent protein; EYFP, enhanced yellow fluorescent protein; HBSS, Hanks' balanced salt solution; ERK, extracellular signal-regulated kinase.

receptor and CaM both in a recombinant protein expression cell system and in the brain. A proteomics approach was used for the discovery of protein-protein interactions between the A$_{2A}$ receptor and CaM in rat brain, whereas BRET in transfected cells demonstrated a direct interaction between CaM and this receptor. Furthermore, by using BRET and sequential resonance energy transfer (SRET) techniques and analyzing MAPK signaling in transfected cells, evidence was obtained for CaM-A$_{2A}$-D$_2$ receptor oligomerization and a selective Ca^{2+}-mediated modulation of A$_{2A}$ and D$_2$ receptor function in the A$_{2A}$-D$_2$ receptor heteromer.

EXPERIMENTAL PROCEDURES

Animals—Male Sprague-Dawley rats (250 g) were obtained from Harlan (Barcelona, Spain). Procedures involving animals were in accordance with the guidelines established by the normative of the European Council (86/609/EEC). The experimental design was approved by the Ethical Committee for Animal Testing of the University of Navarra (060/07).

Membrane Protein Purification—Animals were killed by decapitation, and the brains were rapidly removed. To obtain P2 membrane proteins, the striatum was dissected out and homogenized with a glass-Teflon homogenizer in ice-cold 0.32 M sucrose, 10 mM Hepes (pH 7,4), 2 mM EDTA, and complete protease inhibitors (Roche Applied Science). After spinning at 1,000 × g for 15 min, the supernatant was removed and centrifuged at 200,000 × g for 15 min to yield the crude membrane pellet (P2). The pellet was resuspended in homogenization buffer and spun again at 200,000 × g to yield washed crude membrane pellet (P2′).

Immunoprecipitation—The pellet containing membrane proteins (P2′) was solubilized in immunoprecipitation buffer (phosphate-buffered saline (pH 7.4), complete protease inhibitor mixture, and 1% Igepal Ca-630 (Sigma)) for 1 h at 4 °C. Protein concentration was determined by the BCA method (Pierce). A total amount of 0.5 mg of protein was used for immunoprecipitation. Samples were pretreated with 30 μl of protein A/G-agarose beads (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) with gentle rocking for 1 h at 4 °C and centrifuged at 10,000 × g to remove the beads. Membrane proteins were incubated with 5 μg of polyclonal anti A$_{2A}$ receptor (Affinity Bioreagents, bioNova Científica, Madrid, Spain) or with 5 μg of normal rabbit IgG (Upstate, Charlottesville, VA) for 90 min, and then 30 μl of Protein A/G beads were added and left for 16 h at 4 °C with gentle rocking. Immunoprecipitated proteins were washed three times with immunoprecipitation buffer.

Proteomic Analysis—Immunoprecipitated proteins were analyzed in the Proteomic Laboratory of CIMA. Briefly, proteins were eluted by incubation with 100 mM glycine-HCl (pH 2.5) for 10 min at room temperature with gentle rocking. The samples were centrifuged at 10,000 × g for 1 min, and the supernatant content was precipitated with 25% trichloroacetic acid for 20 min at 4 °C. After spinning at 10,000 × g for 15 min, the pellet was washed twice with precooled acetone, completely dried in a SpeedVac, and resuspended in 30 μl of 100 mM ammonium bicarbonate. Proteins were reduced with 10 mM dithiothreitol for 30 min at 56 °C, alkylated with 55 mM iodoac-

etamide for 20 min in darkness, and finally digested with trypsin 1:50 (v/v) for 16 h at 37 °C. Peptide mass fingerprinting was obtained from tryptic digests by liquid chromatography-electrospray ionization-tandem mass spectrometry analysis (27). A peak list was generated by ProteinLynx Global Server 2.1 (Waters, Milford, MA). A data base search was done with ProteinLynx Global Server 2.1 (Waters) and Phenyx for raw data and mzXML data, respectively. The data base used in this study was SwissProt.

Cell Culture—HEK-293T cells were grown in Dulbecco's modified Eagle's medium supplemented with 2 mM L-glutamine, 100 units/ml penicillin/streptomycin, and 5% (v/v) heat-inactivated fetal bovine serum (all supplements were from Invitrogen). Cells were maintained at 37 °C in an atmosphere of 5% CO$_2$ and were passaged when they were 80–90% confluent (*i.e.* approximately twice per week).

Mutant A$_{2A}$ Receptors, Fusion Proteins, and Expression Vectors—The sequence R^{291}IREFR^{296}QTFR^{300} in the C-terminal domain of the human A$_{2A}$ receptor was mutated to A^{291}IREFA^{296}QTFA^{300} by site-directed mutagenesis (Cellogenetics, Ijamsville, MD). The human cDNAs for A$_{2A}$, mutant A$_{2A}$, which is denoted as A$_{2A}$R^{AAA}, D$_2$, and A$_1$ receptors, cloned into pcDNA3.1, were amplified without their stop codons using sense and antisense primers harboring unique EcoRI and BamHI sites to clone A$_{2A}$ receptor, mutant A$_{2A}$ receptor, or A$_1$ receptor in Rluc vector and EcoRI and KpnI to clone D$_2$ receptor in Rluc or EYFP vectors. The amplified fragments were subcloned to be in frame into restriction sites of pcDNA3.1Rluc and pEYFP-N1 (enhanced yellow variant of GFP; Clontech) vectors, resulting in the plasmids A$_{2A}$RRluc, A$_{2A}$R^{AAA}Rluc, A$_1$RRluc, D$_2$RRluc, and D$_2$RYFP. The cDNA encoding the human EYFP-CaM (CaMYFP) fusion protein was kindly provided by Dr. Carles Enrich (Hospital Clinic de Barcelona, Spain). CaM was subsequently subcloned into the pGFP^2-C1 (BioSignal Packard, Montreal, Canada) using EcoRI and BamHI, resulting in the GFP^2-CaM plasmid. The cDNA encoding the 5HT$_{2B}$R-YFP fusion protein was kindly provided by Dr. Irma Nardi (University of Pisa, Italy). Expression of constructs was tested by confocal microscopy (see "Results"), and the receptor functionality was tested by second messengers, ERK1/2 phosphorylation, and cAMP production, as described previously (12, 14) (data not shown).

Transient Transfection and Protein Determination—HEK-293T cells growing in 6-well dishes were transiently transfected with the corresponding fusion protein cDNA by the polyethyleneimine (Sigma) method. Cells were incubated (4 h) with the corresponding cDNA together with polyethyleneimine (5 μl/μg cDNA of 10 μM polyethyleneimine) and 150 mM NaCl in a serum-free medium. After 4 h, the medium was changed to a fresh complete culture medium. Forty-eight hours after transfection, cells were washed twice in quick succession in HBSS with 10 mM glucose, detached by scraping, and resuspended in the same buffer unless otherwise indicated. To control the cell number, sample protein concentration was determined using a Bradford assay kit (Bio-Rad), using bovine serum albumin as the standard protein. Cell suspensions (20 μg of protein) in HBSS buffer containing 1.26 mM CaCl$_2$ or, when indicated, in Ca^{2+}-free HBSS buffer were distributed into 96-well micro-

plates; black plates with a transparent bottom were used for fluorescence determinations, whereas white plates were used for BRET and SRET experiments.

BRET Assays—HEK-293T cells were transiently co-transfected with the indicated amounts of plasmid cDNAs corresponding to the indicated fusion proteins (see figure legends). To quantify fluorescence proteins, cells (20 μg of protein) were distributed in 96-well microplates (black plates with a transparent bottom), and fluorescence was read at 400 nm in a Fluo Star Optima Fluorimeter (BMG Labtechnologies, Offenburg, Germany) equipped with a high energy xenon flash lamp, using a 10-nm bandwidth excitation filter. Receptor fluorescence expression was determined as fluorescence of the sample minus the fluorescence of cells expressing protein-Rluc alone. For BRET measurements, the equivalent of 20 μg of cell protein was distributed in 96-well microplates (Corning 3600, white plates; Sigma), and 5 μM coelenterazine H (Molecular Probes, Inc., Eugene, OR) was added. After 1 min of adding coelenterazine H, the readings were collected using a Mithras LB 940, which allows the integration of the signals detected in the 485-nm short (440–500 nm) and the 530-nm long (510–590 nm) wavelength filters. To quantify receptor-Rluc expression, luminescence readings were performed after 10 min of adding 5 μM coelenterazine H. The same protocol was used to determine BRET with membranes obtained from cells (48 h post-transfection) disrupted using a Polytron homogenizer (PTA 20 TS rotor, setting 3; Kinematica, Basel, Switzerland). Disruption was performed for three 5-s periods in 10 volumes of free Ca^{2+} HBSS, pH 7.4, containing a proteinase inhibitor mixture (Sigma). Cell debris were eliminated, membranes were obtained by centrifugation at $105,000 \times g$ (40 min, 4 °C), and the pellet was resuspended and recentrifuged under the same conditions. The net BRET is defined as (long wavelength emission/short wavelength emission) $-$ *Cf*, where *Cf* corresponds to long wavelength emission/short wavelength emission for the Rluc construct expressed alone in the same experiment.

SRET Experiments—HEK-293T cells were transiently co-transfected with the indicated amounts of plasmid cDNAs, corresponding to the indicated fusion proteins (see the legend for Fig. 6). Using aliquots of transfected cells (20 μg of protein), three different determinations were performed in parallel. First, we performed quantification of protein-YFP expression by determination of the fluorescence due to protein-YFP. Cells distributed into 96-well microplates (black plates with a transparent bottom) were read in a Fluostar Optima fluorimeter (BMG Labtechnologies, Offenburg, Germany) equipped with a high energy xenon flash lamp, using an excitation filter at 485 nm and 10-nm bandwidth emission filters corresponding to 510 nm (506–515 nm) (Ch1) and 530 nm (527–536 nm) (Ch2). The contribution of the GFP^2 and YFP proteins alone to the two detection channels (spectral signature) (28) was measured in experiments with cells expressing only one of these proteins and normalized to the sum of the signal obtained in the two detection channels. The spectral signatures of the different receptors fused to either GFP^2 or YFP did not vary significantly from the determined spectral signatures of the fluorescent proteins alone. For protein-YFP expres-

sion quantification, linear unmixing was done taking into account the spectral signature as described by Zimmermann *et al.* (28, 29) to separate the two emission spectra; the sample fluorescence is the fluorescence calculated as described minus the fluorescence of cells expressing only protein-Rluc and protein-GFP^2. Second, we performed quantification of protein-Rluc expression by determination of the luminescence due to protein-Rluc. Cells were distributed in 96-well microplates (Corning 3600), and luminescence was determined 10 min after the addition of 5 μM coelenterazine H in a Mithras LB 940 multimode reader (Berthold Technologies, DLReady, Germany). Third, we performed SRET^2 measurements. Cells were distributed in 96-well microplates (Corning 3600), and 5 μM DeepBlueC (Molecular Probes) was added. The SRET^2 signal was collected using a Mithras LB 940 reader with detection filters for short wavelength (400 nm (370–450 nm)) and long wavelength (530 nm (510–590 nm)). By analogy with BRET, net SRET is defined as (long wavelength emission/short wavelength emission) $-$ *Cf*, where *Cf* corresponds to long wavelength emission/short wavelength emission for cells expressing protein-Rluc, protein-GFP^2, and the other protein partner not fused to a fluorescence protein (similar values were obtained measuring *Cf* in cells expressing protein-Rluc only and protein-GFP^2). Linear unmixing was done for SRET^2 quantification, taking into account the spectral signature (28) to separate the two fluorescence emission spectra.

Immunostaining—For immunocytochemistry, transiently transfected HEK-293T cells were fixed in 4% paraformaldehyde for 15 min and washed with phosphate-buffered saline containing 20 mM glycine (buffer A) to quench the aldehyde groups. Then, after permeabilization with buffer A containing 0.2% Triton X-100 for 5 min, cells were treated with phosphate-buffered saline containing 1% bovine serum albumin. After 1 h at room temperature, protein-Rluc was labeled with the primary mouse monoclonal anti-Rluc antibody (1:100; Chemicon, Billerica, MA) for 1 h, washed, and stained with the secondary antibody Cy3 donkey anti-mouse (1:100; Jackson Immunoresearch Laboratories, West Grove, PA). CaMYFP was detected by its fluorescence properties. Samples were rinsed and observed in a Leica SP2 confocal microscope (Leica Microsystems, Mannheim, Germany).

ERK Phosphorylation Assay—Cells were grown in 25-cm^2 flasks to 80% confluence and cultured in serum-free medium for 16 h before the addition of any agent. Cells resuspended in HBSS buffer containing 1.26 mM $CaCl_2$ were treated or not with 1 μM ionomycin for 3 min before the addition of the following agonists: A$_{2A}$ receptor agonist CGS2168 (200 nM), the D$_2$ receptor agonist quinpirole (1 μM), or a mixture of both ligands for 5 min. Cells were rinsed with ice-cold phosphate-buffered saline and lysed by the addition of 500 μl of ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, 50 mM NaF, 150 mM NaCl, 45 mM β-glycerophosphate, 1% Triton X-100, 20 μM phenyl-arsine oxide, 0.4 mM $NaVO_4$, and protease inhibitor mixture). The cellular debris was removed by centrifugation at $13,000 \times g$ for 5 min at 4 °C, and the protein was quantified by the bicinchoninic acid method using bovine serum albumin dilutions as a standard. To determine the level of ERK1/2 phosphorylation, equivalent amounts of protein (10 μg) were separated by electrophoresis

TABLE 1
Peptides identical to the rat calmodulin sequence identified by liquid chromatography-electrospray ionization-tandem mass spectrometry

Sequence	Position	z	dm/z	z-Score	p value
ADQLTEEQIAEFK	2–14	2	−0.014	11.76	1.45E−30
DTDSEEEIR	79–87	2	−0.035	4.16	4.8E−4

on a denaturing 7.5% SDS-polyacrylamide gel and transferred onto polyvinylidene difluoride membranes. The membranes were then probed with a mouse anti-phospho-ERK1/2 antibody (1:2500; Sigma). In order to rule out the possibility that the differences observed were due to the application of unequal amounts of lysates, polyvinylidene difluoride blots were stripped and probed with a rabbit anti-ERK1/2 antibody that recognizes both phosphorylated and nonphosphorylated ERK1/2 (1:40,000; Sigma). Bands were visualized by the addition of anti-mouse horseradish peroxidase-conjugated (Dako, Glostrup, Denmark) or anti-rabbit horseradish peroxidase-conjugated (Sigma) secondary antibodies, respectively, and SuperSignal West Pico Chemiluminescent Substrate (Pierce). Band densities were quantified with a LAS-3000 imaging system (Fujifilm), and the level of phosphorylated ERK1/2 isoforms was normalized for differences in loading using the total ERK protein band intensities. Quantitative analysis of detected bands was performed by Image Gauge version 4.0 software. One-way analysis of variance and Student's t test for unpaired samples were used for statistical comparisons.

RESULTS

Identification of an Interaction between CaM and the A$_{2A}$ Receptor—According to the CaM target data base (available on the World Wide Web), the sequence RIREFRQTFR, which is present in the proximal part of the C terminus of the A$_{2A}$ receptor, has a high probability to bind to CaM. In fact, we recently demonstrated that a synthetic peptide with the same sequence forms non-covalent complexes with bovine CaM (24). A proteomics approach was then used to find *in situ* evidence of direct interactions between the A$_{2A}$ receptor and CaM in the brain. Samples from rat striatal membranes were immunoprecipitated using an antibody directed against a synthetic peptide of the A$_{2A}$ receptor C terminus, SHGDMGLPDVELLSHELK, which does not overlap with the putative CaM-binding motif. Co-immunoprecipitates were digested with trypsin, and the resulting peptides were analyzed by mass spectrometry, as described under "Experimental Procedures." Among other peptides, two corresponding to the sequence of rat CaM (P62161) were detected after co-immunoprecipitation with the specific polyclonal antibody but not with rabbit IgG (Table 1). The significance of the hits was confirmed by the low p values for both the 13-mer and the 9-mer peptides, which collectively covered 15% of the rat CaM sequence (Table 1). These results suggest that CaM and the A$_{2A}$ receptor may interact, but the existence of a third bridging protein cannot be ruled out. For this purpose, BRET assays were performed in cells transfected with the cDNAs for the A$_{2A}$RRluc and CaMYFP fusion proteins. The hyperbola obtained upon increasing the YFP/Rluc ratio (Fig. 1A) indicates that a specific interaction between CaM


FIGURE 1. **Identification of CaM-A$_{2A}$ and CaM-D$_2$ receptor oligomers by BRET experiments.** BRET saturation curves were performed using HEK-293 cells co-expressing A$_{2A}$RRluc and CaMYFP (*triangles*) (A) or D$_2$RRluc and CaMYFP (*inverted triangles*) (B) or A$_1$RRluc and CaMYFP (*squares*). Co-transfections were performed with increasing amounts of plasmid-YFP (0.1–1 μg of cDNA), whereas the plasmid-Rluc construct was maintained constant (0.6 μg of cDNA for A$_{2A}$RRluc, 1 μg of cDNA for D$_2$RRluc, and 0.7 μg of cDNA for A$_1$RRluc). Both fluorescence and luminescence for each sample were measured before every experiment to confirm similar donor expressions (about 100,000 luminescent units) while monitoring the increase in acceptor expression. The relative amount of acceptor is given as the ratio between the fluorescence of the acceptor (YFP) and the luciferase activity of the donor (Rluc). BRET data are expressed as means ± S.D. of 4–8 different experiments grouped as a function of the amount of BRET acceptor.

and the A$_{2A}$ receptor can occur in living cells. Similar experiments were performed using D$_2$RRluc and CaMYFP to confirm that these two proteins may establish direct molecular interactions (Fig. 1B). The specificity of the CaM and A$_{2A}$ receptor or CaM and D$_2$ receptor interactions in HEK cells was confirmed by the nonspecific (linear) BRET signal obtained when assaying A$_1$RRluc and CaMYFP (Fig. 1). To demonstrate that the A$_{2A}$ receptor sequence RIREFRQTFR acts as a CaM binding domain, BRET competition experiments were performed in cells transfected with the cDNAs for the A$_{2A}$RRluc and CaMYFP fusion proteins (amounts adjusted to give values around the BRET$_{50}$) and increasing amounts of cDNA corresponding to the wild type A$_{2A}$R or to the A$_{2A}$R^{AAA} (RIREFRQTFR mutated to AIREFAQTFA). As expected, the A$_{2A}$ receptor did decrease BRET values by competing with A$_{2A}$RRluc for its binding to CaMYFP, whereas A$_{2A}$R^{AAA} did not (Fig. 2A). Accordingly, in cells expressing A$_{2A}$R^{AAA}Rluc and CaMYFP, a linear and negligible BRET was detected in the absence or in the presence of ionomycin (Fig. 2B).

FIGURE 2. **Identification of the A$_{2A}$ receptor CaM binding site.** *A*, BRET competition experiments were performed with HEK-293 cells transfected with A$_{2A}$RRluc (0.6 μg of cDNA), CaMYFP (0.6 μg of cDNA), and increasing amounts of cDNA corresponding to A$_{2A}$R (*white bars*) or A$_{2A}$R^{AAA} (R^{291}IREFR^{296}QTFR^{300} mutated to A^{291}IREFA^{296}QTFA^{300}; *black bars*). Both fluorescence and luminescence for each sample were checked to confirm similar donor and acceptor expression (about 100,000 luminescent units and 10,000 fluorescence units). A$_{2A}$R and A$_{2A}$R^{AAA} receptor expression was monitored by Western blot (not shown). *B*, BRET saturation curves were performed with HEK-293 cells co-expressing A$_{2A}$R^{AAA}Rluc (0.6 μg of cDNA) and increasing amounts of CaMYFP (0.1–1 μg of cDNA) and untreated (*white symbols*) or treated (10 min; *black symbols*) with 1 μM ionomycin in HBSS buffer containing 1.26 mM CaCl$_2$. Both fluorescence and luminescence of each sample were checked to confirm similar donor expressions (about 100,000 luminescent units) while monitoring the increase in acceptor expression. The relative amount of acceptor is given as the ratio between the fluorescence of the acceptor (YFP) and the luciferase activity of the donor (Rluc). BRET data are expressed as means ± S.D. of 4–6 different experiments grouped as a function of the amount of BRET acceptor. Results are compared with the curve obtained for A$_{2A}$RRluc and CaMYFP (*dotted line*; see Fig. 1*A*).

CaM Interacts with A$_{2A}$ and D$_2$ Receptors at the Plasma Membrane—Immunolocalization of receptors and CaM were performed in co-transfected HEK cells. When expressed in the absence of receptors, CaM showed a cytosolic localization (Fig. 3). Co-expression of CaM and any of the two receptors did not modify the localization of the receptor. On the other hand, a significant membrane localization of CaM was only observed when the protein was co-expressed with either A$_{2A}$ or D$_2$ receptors (Fig. 3). The translocation of CaM to the plasma membrane did not take place when co-expressed with the A$_1$ receptor (Fig. 3), which is not able to establish molecular interactions with the protein (see above). Treatment of cells with a Ca^{2+}-free buffer and EDTA or treatment with ionomycin did not modify colo-

calization of CaM and A$_{2A}$ or D$_2$ receptors in cell membranes (Fig. 3).

Effect of Ca^{2+} Levels on the Interaction between CaM and A$_{2A}$ or D$_2$ Receptors—BRET experiments were performed to give some insight into the role of Ca^{2+} in the interaction of CaM with either A$_{2A}$ or D$_2$ receptors. In cells co-expressing D$_2$RRluc and CaMYFP, resuspended in a medium containing 1.26 mM CaCl$_2$, ionomycin treatment led to significant decreases in BRET measurements obtained after periods of incubation of 2, 5, and 10 min (Fig. 4*B*). In cells co-expressing A$_{2A}$RRluc and CaMYFP, ionomycin treatment also led to significant decreases in BRET measurements at 2 and 5 min of preincubation. In contrast, with a longer period of incubation (10 min), the BRET signal for A$_{2A}$RRluc and CaMYFP increased significantly above that found in untreated cells (Fig. 4*A*). On the one hand, these data indicate that Ca^{2+} is not needed for CaM to be able to interact with A$_{2A}$ or D$_2$ receptors. On the other hand, the ionophore-induced increase in intracellular Ca^{2+} concentration does not disrupt the oligomerization of CaM with the receptors but leads to conformational changes in the CaM molecule and/or the receptors that alter the distance between Rluc (fused to the C terminus of the D$_2$ or A$_{2A}$ receptors) and YFP (fused to CaM). The observed effects are not due to the Ca^{+2} toxicity or changes in the membrane structure, since they were also observed in a cell-free system (Fig. 4*D*). Moreover, ionomycin did not induce significant changes in BRET measurements in cells co-expressing A$_1$RRluc and CaMYFP (Fig. 4*C*).

Interactions of CaM with the A$_{2A}$-D$_2$ Receptor Heteromer—By means of BRET competition experiments performed with cells expressing A$_2$RRluc and CaMYFP (with expression levels adequate to give a suboptimal BRET value), the increase in D$_2$ receptor expression (tested by Western blot experiments) did not modify the BRET signal due to A$_2$RRluc and CaMYFP (Fig. 5*A*). Analogously, increasing the expression of CaM did not modify the BRET signal due to A$_2$RRluc and D$_2$RYFP (Fig. 5*B*). As indicated in the Introduction, CaM seems to interact with the Arg-rich epitope of the 3IL of the D$_2$ receptor that is also involved in A$_{2A}$-D$_2$ receptor heteromerization (see the Introduction). In fact, competition assays demonstrated that increasing amounts of A$_{2A}$ receptor led to significant reduction in the BRET signal due to the interaction between the D$_2$ receptor and CaM (Fig. 5*C*). However, a differential effect was obtained depending on the isoform of the D$_2$ receptor (D$_{2S}$ or D$_{2L}$). On the one hand, the BRET signal between D$_{2L}$RRluc and CaMYFP increased with low quantities of A$_{2A}$ receptor but decreased dose-dependently with higher quantities of A$_{2A}$ receptor. On the other hand, using the pair D$_{2S}$RRluc-CaMYFP, a dose-dependent decrease in BRET was found. These findings correlate with the potential ability of CaM and A$_{2A}$ receptors to bind to any of the two Arg-rich epitopes of the 3IL of the D$_{2L}$ receptor (one of which is not present in the D$_{2S}$ structure; see "Discussion"). The specificity of these effects was demonstrated by the independence of the BRET signal with increasing expression of the A$_1$ receptor (Fig. 5*C*).

Oligomerization of CaM, A$_{2A}$, and D$_2$ Receptors—To test the possible existence of CaM-A$_{2A}$-D$_2$ receptor oligomerization, the recently described SRET technique was used (29).

FIGURE 3. **Membrane colocalization of CaM with A$_{2A}$ or D$_2$ receptors.** Co-transfected HEK-293 cells were washed and resuspended for 2.5 h in HBSS buffer containing 1.26 mM CaCl$_2$ (*A–D* and *I–L*) or in a Ca^{+2}-free HBSS buffer containing 1 mM EDTA (*E–H*). *A, E,* and *I,* confocal microscopy images of HEK-293T cells expressing (from *left* to *right* in each *panel*) CaMYFP (0.6 μg of cDNA), A$_{2A}$RRluc (1 μg of cDNA), or D$_2$RRluc (1 μg of cDNA). *B–D, F–H,* and *J–L,* confocal microscopy images of HEK-293T cells co-transfected with the above described amounts of cDNA for CaMYFP and A$_{2A}$RRluc (*B, F,* and *J*), CaMYFP and D$_2$RRluc (*C, G,* and *K*), or CaMYFP and A$_1$RRluc (1 μg of cDNA) (*D, H,* and *L*). Ionomycin-treated cells (10 min prior to fixation) are shown in *I–L*. CaM was identified by YFP fluorescence (*green images*), and receptor-Rluc constructs were identified by immunocytochemistry (using a monoclonal anti-Rluc primary antibody and a cyanine-3-conjugated secondary antibody). Colocalization (*yellow*) is shown in the *right panels*.


FIGURE 4. **Effect of intracellular Ca^{2+} on the interaction between CaM and A$_{2A}$ or D$_2$ receptors detected by BRET experiments.** *A–C,* BRET saturation curves were performed using HEK-293 cells co-expressing A$_{2A}$RRluc and CaMYFP (*A*), D$_2$RRluc and CaMYFP (*B*), or A$_1$RRluc and CaMYFP as negative control (*C*) (see the legend to Fig. 1). In all cases, cells were treated with HBSS buffer containing 1.26 mM CaCl$_2$ and 1 μM ionomycin at 10 (*blue*), 5 (*green*), or 2 (*red*) min before BRET determination. BRET saturation curves were compared with the one obtained in the absence of ionomycin (*dotted line*; see Fig. 1). The relative amount of acceptor is given as the ratio between the fluorescence of the acceptor (YFP) and the luciferase activity of the donor (Rluc). BRET data are expressed as means ± S.D. of 4–8 different experiments grouped as a function of the amount of BRET acceptor. *D,* HEK-293 cells were transfected with 0.6 μg of cDNA for A$_{2A}$RRluc (*A$_{2A}$R*) or 1 μg of cDNA for D$_2$RRluc (*D$_2$R*) and 1 μg of cDNA of CaMYFP, and membranes were obtained 48 h after transfection. Membranes were resuspended in free Ca^{2+} HBSS buffer, and 1.26 mM CaCl$_2$ was added for the indicated times before BRET determination. BRET data are expressed as means ± S.E. of five different experiments. Significant differences over ionomycin-non-treated cells were calculated by one-way analysis of variance and Bonferroni test (*, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.005$).

In SRET^2, the oxidation of an Rluc substrate triggers GFP^2 acceptor excitation by BRET^2 and subsequent energy transfer to a YFP FRET acceptor. SRET^2 was attempted using A$_{2A}$RRluc, CaMGFP^2, D$_2$RYFP, and DeepBlueC as Rluc substrate. SRET^2 would only occur if the two acceptor/donor pairs, A$_{2A}$RRluc/CaMGFP^2 and CaMGFP^2/D$_2$RYFP, are well oriented at a distance of less than 10 nm. A SRET saturation curve obtained by augmenting D$_2$RYFP expression while maintaining the same A$_{2A}$RRluc/CaMGFP^2 ratio is shown in Fig. 6. To obtain optimal results (see Ref. 29), cells were transfected with an amount of cDNA (0.6 μg) for A$_{2A}$RRluc giving readouts of about 100,000 luminescent units, an amount of cDNA (0.4 μg) for CaMGFP^2 giving about 6,000 fluorescent units, and increasing amounts of cDNA (0.5–6 μg) for D$_2$RYFP (giving a range of 500–8,000 fluorescence units). From the saturation curve (Fig. 6), apparent SRET$_{max}$ (0.29 ± 0.03) and apparent SRET$_{50}$ (0.010 ± 0.006) values were calculated. To prove whether SRET was possible when substituting A$_{2A}$ receptors by A$_1$ receptors, cells were transfected with 0.7 μg of cDNA for

FIGURE 5. **CaM interaction with A$_{2A}$-D$_2$ receptor heteromers detected by BRET competition experiments.** BRET competition experiments were performed with HEK-293 cells expressing donor and acceptor constructs to give submaximal BRET values. *A*, cells were co-transfected with the cDNA corresponding to A$_{2A}$RRluc (0.6 μg) and CaMYFP (0.4 μg) and increasing amounts of D$_2$R cDNA as competitor (0.3–2.5 μg), whose expression was monitored by Western blotting (*bottom*) mBU, milli-BRET units. *B*, cells were cotransfected with the cDNA corresponding to A$_{2A}$RRluc (0.6 μg) and D$_{2L}$RYFP (1.5 μg) and increasing amounts of cDNA of CaMGFP^2 as competitor (0.2–1.5 μg), whose expression was monitored by measuring the GFP^2 fluorescence (1,000–20,000 fluorescence units), as described under "Experimental Procedures." To determine the YFP fluorescence in BRET experiments, the spectral signature was considered to control the GFP^2 contribution to the detection channel (28, 29). Cells were cotransfected with the cDNA corresponding to D$_{2L}$RRluc (1 μg; *C*) or D$_{2S}$RRluc (0.8 μg; *D*) and CaMYFP (0.4 μg) and increasing amounts of cDNA of A$_{2A}$R as competitor (*black bars*) or A$_1$R as negative control (*white bars*), whose expression was monitored by dot blotting (results not shown). At the *top* of each *panel*, a scheme depicts the expressed proteins in BRET competition assays.

A$_1$RRluc (100,000 luminescent units), 0.4 μg of cDNA for CaMGFP^2 (6,000 fluorescent units), and 0.5–6 μg of cDNA for D$_2$RYFP (500–9,000 fluorescence units). The possible formation of a trimer in which the D$_2$ receptor was substituted by the serotonin 5-HT$_{2B}$ receptor was tested using cells

transfected with 0.6 μg of cDNA for A$_{2A}$RRluc, 0.4 μg of cDNA for CaMGFP^2, and 0.5–6 μg of cDNA for the 5-HT$_{2B}$ receptor (500–9,000 fluorescence units). Using these two combinations of fusion proteins, a very low and non-saturating (linear) SRET was observed, which indicates that oligomerization

FIGURE 6. **SRET for CaM, A$_{2A}$ receptor and D$_2$ receptor in living cells.** SRET saturation curves were performed in HEK-293 cells expressing A$_{2A}$R-Rluc (0.75 μg of cDNA), CaMGFP^2 (0.6 μg of cDNA), and increasing amounts of D$_2$RYFP (0.5–5 μg of the cDNA). Net SRET was obtained by monitoring the YFP fluorescence emission after coelenterazine H addition, with subtraction of the value obtained with cells expressing the same amount of A$_{2A}$R-Rluc and CaMGFP^2. Significant net SRET was detected for A$_{2A}$RRluc-CaMGFP^2-D$_2$RYFP coupling, whereas negligible or linear net SRET was obtained in cells expressing equivalent amounts (equivalent fluorescence and luminescence units) of A$_{2A}$RRluc, CaMGFP^2, and 5HT2BYFP or A$_1$RRluc, CaMGFP^2, and D$_2$RYFP, which were used as negative controls. Values, expressed as net SRET, represent means $\pm$ S.E. of five independent experiments performed in triplicate. At the *top*, a *scheme* depicts the expressed proteins in SRET assays.

of CaM, A$_1$, and D$_2$ receptors or CaM, A$_{2A}$, and 5-HT$_{2B}$ receptors does not occur.

Effects of Intracellular Ca^{2+} on CaM-A$_{2A}$-D$_2$ Receptor Oligomerization—BRET was measured in the presence and in the absence of ionomycin in cells co-transfected with A$_{2A}$RRluc and D$_2$RYFP. The calcium ionophore led to qualitative changes in the BRET curves (Fig. 7A) similar to those in the experiments with cells co-expressing A$_{2A}$RRluc and CaMYFP (see Fig. 4A). Thus, the BRET signal for A$_{2A}$RRluc and D$_2$RYFP decreased at shorter times of incubation with ionomycin, whereas it increased at longer times (Fig. 7A). These results suggest that Ca^{2+} binding to CaM induces conformational changes in the A$_{2A}$ receptor such that the distance between the donor Rluc (fused to the C terminus of the A$_{2A}$) and the acceptor YFP is modified. Taking all of the results into account, the most probable scenario is the existence of a CaM-A$_{2A}$-D$_2$ receptor oligomeric complex, Ca^{2+} binding to CaM being unable to disrupt A$_{2A}$-D$_2$ receptor heteromers. To further test this possibility, SRET^2 for A$_{2A}$RRluc-CaMGFP^2-D$_2$RYFP was measured in cells treated with ionomycin. As shown in Fig. 6B, a positive SRET^2 was detected in the presence of ionomycin with an apparent SRET$_{max}$ of 0.24 $\pm$ 0.08 and an apparent SRET$_{50}$ of 0.051 $\pm$ 0.003. Therefore, calcium binding to CaM led to a decrease in the apparent SRET$_{max}$ and an increase in the apparent SRET$_{50}$ values. CaM-A$_{2A}$-D$_2$ receptor oligomers seem to be stable complexes that are not disrupted by calcium binding to CaM.

Effects of Intracellular Ca^{2+} on the Function of A$_{2A}$-D$_2$ Receptor Heteromers—To test whether calcium binding to CaM-A$_{2A}$-D$_2$ receptor oligomers modifies receptor functionality, MAPK pathway signaling in cells expressing CaM and A$_{2A}$R, D$_2$R, or both receptors was analyzed. ERK1/2 phosphorylation was determined in cells treated with a 200 nM concentration of the A$_{2A}$ receptor agonist CGS21680, and/or with 1 μM D$_2$ receptor agonist quinpirole in the presence and in the absence of 1 μM ionomycin. As shown in Fig. 8A, activation of A$_{2A}$ or D$_2$ receptors, in cells transfected with low amounts of cDNA for CaM (0.3 μg) and expressing A$_{2A}$ or D$_2$ receptors, induced similar ERK1/2 phosphorylation in the absence or in the presence of ionomycin. On the other hand, in cells transfected with 0.3 μg of cDNA for CaM and expressing the two receptors, a different effect was obtained in the absence or in the presence of ionomycin. In this case, ionomycin significantly reduced or potentiated ERK1/2 phosphorylation induced by activation of A$_{2A}$ or D$_2$ receptors (Fig. 8B), respectively. The well known antagonistic interaction between A$_{2A}$ and D$_2$ receptors was enhanced upon treatment with ionomycin. Results similar to those in Fig. 8, A and B, were obtained if cells were expressing higher amounts of CaM (1 μg of cDNA; results not shown), indicating that moderate amounts of exogenous CaM are already able to modulate receptor operation. In contrast, the effects of ionomycin were not observed in cells expressing only endogenous CaM (Fig. 8C). Therefore, the effects of ionomycin were dependent on the intracellular levels of CaM. Results similar to those in Fig. 8, A and B, were also obtained using cells in suspension (not adherent cells) (i.e. in the same conditions as those used for BRET and SRET experiments) (results not shown). Overall, the results suggest a correlation between structural changes in the oligomer and the modulation of its functionality exerted by Ca^{+2} binding.

DISCUSSION

Ca^{2+} plays an important role in the physiology of higher order organisms and is involved in the regulation of many cellular events. Various stimuli, such as membrane depolarization or binding of ligands to plasma transmembrane receptors, trigger Ca^{2+} channel opening, which results in a significant influx of Ca^{2+} into the cytosol. Then Ca^{2+}-binding proteins act as sensors and mediators of the initial Ca^{2+} signal. CaM is a highly conserved, soluble, intracellular 17-kDa Ca^{2+}-binding protein, regarded as a major transducer of Ca^{2+} signals in mammalian cells (30). CaM has been shown to bind directly to cytoplasmic domains of plasma membrane proteins, including G-protein-coupled receptors, such as opioid μ, serotonin 5-HT$_{1A}$, acetylcholine muscarinic, and dopamine D$_2$ receptors (21, 31–33). In the present work, we also provide clear evidence for the binding of CaM to adenosine A$_{2A}$ receptors. It was demonstrated that the sequence RIREFRQTFR, which is present in the proximal part of the C terminus of the A$_{2A}$ receptor, is the CaM binding domain in these receptors. Furthermore, we provide evidence for CaM-A$_{2A}$-D$_2$ receptor oligomerization and for a specific Ca^{2+}-dependent modulation of A$_{2A}$-D$_2$ receptor heteromer function. Previous studies have shown that an Arg-rich domain of the N-terminal portion of the 3IL of the D$_2$ receptor is involved in the binding to G$_{i/o}$ proteins, CaM, and the A$_{2A}$

FIGURE 7. **Effect of intracellular Ca^{2+} on the molecular interactions between CaM, A$_{2A}$, and D$_2$ receptors.** *A*, effect of Ca^{2+} levels on the A$_{2A}$-D$_2$ receptor heteromerization detected by BRET. BRET saturation curves were performed with HEK-293 cells co-expressing A$_{2A}$RRluc (0.6 μg of cDNA) and increasing amounts of D$_2$RYFP (0.3–4 μg of cDNA). Cells in HBSS buffer containing 1.26 mM CaCl$_2$ were untreated (*black*) or treated with 1 μM ionomycin for 2 (*red*), 5 (*green*) or 10 (*blue*) min before BRET determination. Both fluorescence and luminescence for each sample were measured to confirm similar donor expressions (about 100,000 luminescent units) while monitoring the increase acceptor expression (1,000–15,000 fluorescent units). The relative amount of acceptor is given as the ratio between the fluorescence of the acceptor (YFP) and the luciferase activity of the donor (Rluc). BRET data are expressed as means ± S.D. of four different experiments grouped as a function of the amount of BRET acceptor. mBU, milli-BRET units. *B*, effect of Ca^{2+} levels on the CaM-A$_{2A}$-D$_2$ receptor oligomerization detected by SRET. SRET saturation curves were performed in HEK-293 cells expressing A$_{2A}$RRluc, CaMGFP^2, and increasing amounts of D$_2$RYFP, as described in the legend to Fig. 6. Cells in HBSS buffer containing 1.26 mM CaCl$_2$ were treated with 1 μM ionomycin for 10 min before SRET determination as described in the legend to Fig. 6, and the SRET saturation curve was compared with the one obtained in the absence of ionomycin (*dotted line*; see Fig. 6).

receptor (14, 20, 22, 24, 34). The binding of CaM to the D$_2$ receptor disrupts G$_{i/o}$ coupling and, therefore, its ability to inhibit the activity of adenylyl cyclase (22). We here report competition of CaM and A$_{2A}$ receptors for the same domain in the D$_2$ receptor. This competition was particularly evident when the short isoform of the D$_2$ receptor was assayed. The two isoforms of the D$_2$ receptor (short and long, D$_{2S}$ and D$_{2L}$, respectively) are generated by alternative splicing (35). D$_{2L}$, the isoform used in most of the experiments of the present study, contains 29 additional amino acid residues within the middle portion of the 3IL. The Arg-rich epitope of the D$_2$ receptor (VLRRRRKRVN) that is able to interact with the A$_{2A}$ receptor is common to both D$_2$ receptor isoforms and is localized in the N-terminal portion of their long 3IL (14, 20). However, there is an additional Arg-rich epitope in the 3IL of D$_{2L}$ (VNRRRVEAA), which is not present in D$_{2S}$ and which can potentially interact with CaM or with the A$_{2A}$ receptor (21). The VNR-


FIGURE 8. **Effect of intracellular Ca^{2+} on A$_{2A}$ receptor-, D$_2$ receptor-, and A$_{2A}$-D$_2$ receptor heteromer-mediated ERK1/2 phosphorylation.** HEK-293 cells expressing A$_{2A}$ receptor (1.2 μg of cDNA) or D$_2$ receptor (1 μg of cDNA) and CaM (0.3 μg of cDNA) (*A*); A$_{2A}$ receptor (1.2 μg of cDNA), D$_2$R (1 μg of cDNA), and CaM (0.3 μg of cDNA) (*B*); or A$_{2A}$ receptor (1.2 μg of cDNA) and D$_2$R (1 μg of cDNA) (*C*) were placed in HBSS buffer containing 1.26 mM CaCl$_2$ and treated 3 min with vehicle or with 1 μM ionomycin before the addition of the A$_{2A}$ receptor agonist CGS21680 (200 nM; CGS), the D$_2$ receptor agonist quinpirole (1 μM), or both. A representative Western blot from ERK1/2 phosphorylation assays, which were performed as described under "Experimental Procedures," is shown. No significant differences in the basal levels were detected by the presence of CaM or CaM plus ionomycin. The immunoreactive bands from 4–6 independent experiments were quantified, and values represent the mean ± S.E. of percentage of increase of phosphorylation over the basal levels (100%) found in ionomycin-untreated or -treated cells. Significant differences of agonist-treated *versus* basal (*) or agonist-treated in the presence *versus* the absence of ionomycin (&) were calculated by one-way analysis of variance and Bonferroni test (* and &, $p < 0.05$; ** and &&, $p < 0.01$; *** and &&&, $p < 0.005$).

RRVEAA peptide interacts in *vitro* with CaM and with a phosphorylated Ser-containing epitope of the C terminus of the A$_{2A}$ receptor that is involved in A$_{2A}$-D$_2$ receptor heteromerization (data not shown). In BRET competition experiments using D$_{2S}$RRluc-CaMYFP, the increase of A$_{2A}$ receptor expression produced a significant decrease of the BRET signal. On the other hand, when co-transfecting the A$_{2A}$ receptor, the BRET signal between D$_{2L}$RRluc and CaMYFP first increased, whereas higher expression levels led to a reduced BRET signal. It is possible that, in the D$_{2L}$ receptor, CaM binds preferentially to the VLRRRKRVN epitope and that increasing quantities of transfected A$_{2A}$ receptor induce, first, translocation of CaM to the VNRRRVEAA epitope, thus leading to an enhancement of the BRET signal. Upon further increase of receptor expression, A$_{2A}$R may also bind to the VNRRRVEAA epitope, with the consequent displacement of CaM from the D$_{2L}$ receptor. The results from BRET competition experiments demonstrating that increasing expression of D$_2$ receptor did not modify the BRET signal due to A$_2$RRluc and CaMYFP and that increasing expression of CaM did not modify the BRET signal due to A$_2$RRluc and D$_2$RYFP were also compatible with the possibility of CaM-A$_{2A}$-D$_2$ receptor oligomerization with A$_{2A}$ receptors able to bind simultaneously to CaM and to the D$_2$ receptor. This was demonstrated with the use of the recently introduced sequential SRET techniques, which allow the demonstration of direct interaction of three protein molecules (29).

The results not only indicated that CaM may interact with A$_{2A}$ receptors in cells that express A$_{2A}$-D$_2$ receptor heteromers but also that the conformation and function of A$_{2A}$-D$_2$ receptor heteromers are modulated by Ca^{2+}. In fact ionomycin, an ionophore able to increase intracellular Ca^{2+}, did affect the energy transfer between A$_{2A}$RRluc and D$_2$RYFP. Agonist-induced conformational modifications in a receptor heteromer can be demonstrated by using resonance energy transfer techniques (36). In the case of the A$_{2A}$-D$_2$ receptor heteromer and by means of the same techniques used in the present study, no energy transfer variations were found after exposure to A$_{2A}$ or D$_2$ receptor agonists (12). Therefore, the ability of BRET techniques to detect Ca^{2+}-triggered conformational changes within the CaM-A$_{2A}$ receptor, CaM-D$_2$ receptor, and CaM-A$_{2A}$-D$_2$ receptor oligomers suggests that Ca^{2+} exerts a strong CaM-dependent control of the function of A$_{2A}$ and D$_2$ receptors and A$_{2A}$-D$_2$ receptor heteromers. Interestingly, Ca^{2+} exerted a selective modulation of A$_{2A}$-D$_2$ receptor heteromer-mediated activation of the MAPK pathway. On the other hand, Ca^{2+} binding to CaM did not individually modulate the receptor-mediated signaling toward the MAPK pathway, and Ca^{2+} significantly modified ERK1/2 phosphorylation induced by activation of A$_{2A}$ or of D$_2$ receptors in cells co-expressing the two receptors. Furthermore, the previously described (18) antagonistic interaction between A$_{2A}$ and D$_2$ receptors was regulated by ionomycin-mediated variation in the intracellular calcium concentration.

The present study demonstrates the existence of oligomeric intermolecular interactions between CaM, A$_{2A}$, and D$_2$ receptors. When not expressed together, A$_{2A}$ or D$_2$ receptors may potentially bind CaM, but in cells expressing the A$_{2A}$-D$_2$ receptor heteromer, CaM binds preferentially to the A$_{2A}$ receptor. Furthermore, CaM transduces Ca^{2+}-dependent changes of MAPK signaling in the CaM-A$_{2A}$-D$_2$ receptor oligomer. This work adds new information about the function of A$_{2A}$-D$_2$ receptor heteromers, which are considered as a target for the development of anti-parkinsonian agents (37).

REFERENCES

1. Agnati, L. F., Ferré, S., Lluis, C., Franco, R., and Fuxe, K. (2003) *Pharmacol. Rev.* **55,** 509–550
2. Pin, J. P., Neubig, R., Bouvier, M., Devi, L., Filizola, M., Javitch, J. A., Lohse, M. J., Milligan, G., Palczewski, K., Parmentier, M., and Spedding, M. (2007) *Pharmacol. Rev.* **59,** 5–13
3. Lee, S. P., O'Dowd, B. F., and George, S. R. (2003) *Life Sci.* **74,** 173–180
4. Rashid, A. J., So, C. H., Kong, M. M., Furtak, T., El-Ghundi, M., Cheng, R., O'Dowd, B. F., and George, S. R. (2007) *Proc. Natl. Acad. Sci. U.S.A.* **104,** 654–659
5. Prinster, S. C., Holmqvist, T. G., and Hall, R. A. (2006) *J. Pharmacol. Exp. Ther.* **318,** 974–981
6. Prinster, S. C., Hague, C., and Hall, R. A. (2005) *Pharmacol. Rev.* **57,** 289–298
7. Ferré, S., Baler, R., Bouvier, M., Caron, M. G., Devi, L. A., Durroux, T., Fuxe, K., George, S. R., Javitch, J. A., Lohse, M. J., Mackie, K., Milligan, G., Pfleger, K. D., Pin, J. P., Volkow, N. D., Waldhoer, M., Woods, A. S., and Franco, R. (2009) *Nat. Chem. Biol.* **5,** 131–134
8. Milligan, G., and Bouvier, M. (2005) *FEBS J.* **272,** 2914–2925
9. Pfleger, K. D., and Eidne, K. A. (2006) *Nat. Methods* **3,** 165–174
10. Kocan, M., See, H. B., Seeber, R. M., Eidne, K. A., and Pfleger, K. D. (2008) *J. Biomol. Screen.* **13,** 888–898
11. Hillion, J., Canals, M., Torvinen, M., Casado, V., Scott, R., Terasmaa, A., Hansson, A., Watson, S., Olah, M. E., Mallol, J., Canela, E. I., Zoli, M., Agnati, L. F., Ibanez, C. F., Lluis, C., Franco, R., Ferre, S., and Fuxe, K. (2002) *J. Biol. Chem.* **277,** 18091–18097
12. Canals, M., Marcellino, D., Fanelli, F., Ciruela, F., de Benedetti, P., Goldberg, S. R., Neve, K., Fuxe, K., Agnati, L. F., Woods, A. S., Ferré, S., Lluis, C., Bouvier, M., and Franco, R. (2003) *J. Biol. Chem.* **278,** 46741–46749
13. Kamiya, T., Saitoh, O., Yoshioka, K., and Nakata, H. (2003) *Biochem. Biophys. Res. Commun.* **306,** 544–549
14. Ciruela, F., Burgueño, J., Casadó, V., Canals, M., Marcellino, D., Goldberg, S. R., Bader, M., Fuxe, K., Agnati, L. F., Lluis, C., Franco, R., Ferré, S., and Woods, A. S. (2004) *Anal. Chem.* **76,** 5354–5363
15. Ferre, S., von Euler, G., Johansson, B., Fredholm, B. B., and Fuxe, K. (1991) *Proc. Natl. Acad. Sci. U.S.A.* **88,** 7238–7241
16. Ferré, S., Fredholm, B. B., Morelli, M., Popoli, P., and Fuxe, K. (1997) *Trends Neurosci.* **20,** 482–487
17. Ferré, S., Ciruela, F., Quiroz, C., Luján, R., Popoli, P., Cunha, R. A., Agnati, L. F., Fuxe, K., Woods, A. S., Lluis, C., and Franco, R. (2007) *Scientific WorldJournal* **7,** 74–85
18. Ferré, S., Quiroz, C., Woods, A. S., Cunha, R., Popoli, P., Ciruela, F., Lluis, C., Franco, R., Azdad, K., and Schiffmann, S. N. (2008) *Curr. Pharm. Des.* **14,** 1468–1474
19. Altamura, A. C., Bassetti, R., Cattaneo, E., and Vismara, S. (2005) *World J. Biol. Psychiatry* **6,** Suppl. 2, 23–30
20. Woods, A. S., and Ferré, S. (2005) *J. Proteome Res.* **4,** 1397–1402
21. Woods, A. S., Ciruela, F., Fuxe, K., Agnati, L. F., Lluis, C., Franco, R., and Ferré, S. (2005) *J Mol. Neurosci.* **26,** 125–132
22. Bofill-Cardona, E., Kudlacek, O., Yang, Q., Ahorn, H., Freissmuth, M., and

Nanoff, C. (2000) *J. Biol. Chem.* **275,** 32672–32680
23. Liu, Y., Buck, D. C., Macey, T. A., Lan, H., and Neve, K. A. (2007) *J. Recept. Signal. Transduct. Res.* **27,** 47–65
24. Woods, A. S., Marcellino, D., Jackson, S. N., Franco, R., Ferré, S., Agnati, L. F., and Fuxe, K. (2008) *J. Proteome Res.* **7,** 3428–3434
25. Woods, A. S. (2004) *J. Proteome Res.* **3,** 478–484
26. Woods, A. S., and Huestis, M. A. (2001) *J. Am. Soc. Mass Spectrom.* **12,** 88–96
27. Muñoz, J., Fernández-Irigoyen, J., Santamaría, E., Parbel, A., Obeso, J., and Corrales, F. J. (2008) *Proteomics* **8,** 1898–1908
28. Zimmermann, T., Rietdorf, J., Girod, A., Georget, V., and Pepperkok, R. (2002) *FEBS Lett.* **531,** 245–249
29. Carriba, P., Navarro, G., Ciruela, F., Ferré, S., Casadó, V., Agnati, L., Cortés, A., Mallol, J., Fuxe, K., Canela, E. I., Lluís, C., and Franco, R. (2008)

30. Vetter, S. W., and Leclerc, E. (2003) *Eur. J. Biochem.* **270,** 404–414
31. Belcheva, M. M., Szùcs, M., Wang, D., Sadee, W., and Coscia, C. J. (2001) *J. Biol. Chem.* **276,** 33847–33853
32. Turner, J. H., Gelasco, A. K., and Raymond, J. R. (2004) *J. Biol. Chem.* **279,** 17027–17037
33. Lucas, J. L., Wang, D., and Sadée, W. (2006) *Pharm. Res.* **23,** 647–653
34. Senogles, S. E., Heimert, T. L., Odife, E. R., and Quasney, M. W. (2004) *J. Biol. Chem.* **279,** 1601–1606
35. Missale, C., Nash, S. R., Robinson, S. W., Jaber, M., and Caron, M. G. (1998) *Physiol. Rev.* **78,** 189–225
36. Vilardaga, J. P., Nikolaev, V. O., Lorenz, K., Ferrandon, S., Zhuang, Z., and Lohse, M. J. (2008) *Nat. Chem. Biol.* **4,** 126–131
37. Müller, C. E., and Ferré, S. (2007) *Recent Pat. CNS Drug Discov.* **2,** 1–21

Nat. Methods **5,** 727–733